Pirfetab 801mg Tablet

Introduction

Pirfetab is a prescription medication that contains the active ingredient Pirfenidone. It is available in tablet form and is marketed under the brand name Pirfetab.

Uses

Pirfetab is primarily used to treat a condition called idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive lung disease that causes scarring of the lung tissue. Pirfetab can help slow down the progression of IPF and improve lung function.

Dosage and Administration

The recommended dosage of Pirfetab is usually 801 mg (two tablets) taken three times a day with food. Your healthcare provider will determine the appropriate dosage based on your individual condition and response to treatment. Follow the instructions provided by your healthcare provider and not exceed the recommended dosage.

Mechanism of Action

The exact mechanism of action of Pirfenidone, the active ingredient in Pirfetab, is not fully understood. However, it is believed to work by reducing inflammation and fibrosis (scar tissue formation) in the lungs. This can help slow down the progression of idiopathic pulmonary fibrosis and improve lung function.

Side Effects

Common side effects may include nausea, diarrhea, rash, and fatigue. These side effects are usually mild and go away on their own. However, if they persist or become bothersome, consult your healthcare provider.

Serious side effects are rare but may include liver problems, allergic reactions, and gastrointestinal bleeding. If you experience any signs of a serious side effect, such as yellowing of the skin or eyes, severe rash, difficulty breathing, or unusual bleeding, seek immediate medical attention.

Drug Interactions

Pirfetab may interact with other medications, including certain antibiotics, antifungal medications, and anticoagulants. Inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products. This will help prevent any potential drug interactions and ensure the safe and effective use of Pirfetab.

Precautions

Before taking Pirfetab, inform your healthcare provider if you have any liver problems, kidney problems, or a history of bleeding disorders. Additionally, inform your healthcare provider about any other medical conditions you may have and any medications you are currently taking.

Pirfetab is not recommended for use during pregnancy or while breastfeeding. It is also contraindicated in patients with a known hypersensitivity to Pirfenidone or any other component of the medication.

Storage

Pirfetab should be stored at room temperature, away from direct sunlight and moisture. Keep the medication out of reach of children and pets. Do not use Pirfetab if it has expired or if the packaging is damaged.

Patient Tips

• Take Pirfetab exactly as prescribed by your healthcare provider. Do not skip doses or take more than the recommended dosage.
• It is recommended to take Pirfetab with food to reduce the risk of stomach upset.
• If you miss a dose, take it as soon as you remember. If it is close to the time for your next dose, skip the missed dose and resume your regular dosing schedule.
• It may take some time to see the full benefits of Pirfetab. Be patient and continue taking the medication as directed by your healthcare provider.
• If you have any questions or concerns about Pirfetab or its use, consult your healthcare provider for further guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Esbriet 267 mg Film-coated Tablets (Health Professionals SmPC) Available at:
• Pirfenidone (Drugs.com) [Accessed 16 Jun. 2024] (online) Available at:
• pirfenidone 801 mg tablet pulmonary fibrosis treatment agents – antifibrotic therapy (RX) [Accessed 22 Jun. 2024] (online) Available at:
• Pirfenidone (MedlinePlus) [Accessed 3 Jun. 2024] (online) Available at:
• Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017 Dec 6;26(146):170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. [Accessed 0 Jun. 2024] Available at: